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Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who
are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach
is now under study in a number of randomized trials. Despite the improved response rates with induction
therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of
post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the
options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of
relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
A 64-year-old previously healthy man presented with
anemia and lytic bone disease and was diagnosed with ISS
stage II IgA kappamyeloma. Cytogenetics at time of diagnosis
revealed monosomy 13, but the ﬂuorescein in situ hybridi-
zation panel was otherwise unremarkable. He received 4
cycles of induction therapy with lenalidomide, bortezomib,
and dexamethasone with concurrent monthly infusions of
zoledronic acid and achieved a very good partial response.
He subsequently underwent autologous stem cell trans-
plantation (ASCT) with melphalan 200 mg/m2.
At the day 100 post-ASCT evaluation he had no evidence
of disease and thus had achieved a compete response. Hewas
started on lenalidomide maintenance, and periodic infusions
of zoledronic acid were continued. The patient tolerated
doses of lenalidomide at 15 mg daily continuously for the
ﬁrst year, but this dose had to be reduced to 10mg during the
second year because of cytopenias.
Two years after the ASCT, a reappearance of the IgA kappa
monoclonal protein was noted on routine follow-up. The
dose of lenalidomide was increased to 25 mg as his counts
were preserved, and dexamethasone was added with a
transient reduction in his M protein, but 3 months later the
patient presented with new onset bone pain. Imagingdgments on page 797.
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ty for Blood and Marrow Transplantation.revealed new areas of lytic disease. Further options for
management of his relapsed disease were discussed with the
patient.
RELAPSE PATTERNS AFTER ASCT
It is well-recognized that relapse after ASCT can take
different forms, and several groups have described these
various relapse patterns. For example, Alegre et al. [1]
retrospectively analyzed 280 patients and categorized them
into 4 patterns: clinically symptomatic disease (66%),
asymptomatic disease characterized by increase in mono-
clonal protein (18%), extramedullary disease (14%), and
plasma cell leukemia (2%). Lenhoff et al. [2] prospectively
followed 397 patients who underwent ASCT from 1994 to
1997 and also documented 4 relapse patterns: insidious
(asymptomatic increase in monoclonal protein, 31%), clas-
sical (increase in monoclonal proteinwith clinical symptoms,
51%), plasmacytoma form (14%), or transformed disease
(plasmacytic leukemia, immunoblastic lymphoma, 4%).
Zamarin et al. [3] performed a retrospective analysis of 273
patients relapsing after ﬁrst ASCT. In contrast to the ﬁrst 2
studies, Zamarin et al. included a new relapse criteria for
patients who were previously in complete remission and
based on free light chain testing. This new criteria speciﬁcally
required development of an abnormal free light chain ratio
and an elevated level of involved free light chain in the
setting of a previously normal free light chain ratio on at least
2 prior measurements. Eighty-ﬁve percent of patients had
asymptomatic relapse/progression, with the remainder
having symptomatic disease associated with aggressive
Table 1
Regimens for Relapsed/Refractory Myeloma
Single Doublet Triplet Combination
Chemotherapy
Bendamustine Len-Dex Len-Bor-Dex D-PACE
Car Bor-Dex Thal-Bor-Dex VD-PACE
Cy Pom-Dex Vel-Cy-Dex VDT-PACE
Dex Car-Dex Len-Cy-Dex DCEP
Methylprednisolone Mel-Pred Bor-Dox-Dex D-BEAM
Thal-Dex Len-Car-Dex
Pom-Car-Dex
Pom-Bor-Dex
Pom-Cy-Dex
Car-Cy-Dex
Bor-Mel-Pred
Thal-Mel-Pred
Vin-Dox-Dex
Len-bendamustine-Dex
Bor indicates bortezomib; Car, carﬁlzomib; Cy, cyclophosphamide; Dex,
dexamethasone; Dox, liposomal doxorubicin; Len, lenalidomide; Mel,
melphalan; Pom, pomalidomide; Pred, prednisone; Thal, thalidomide; Vin,
vincristine; D-PACE, dexamethasone, cyclophosphamide, doxorubicin,
cisplatin, etoposide; VD-PACE, D-PACE plus bortezomib; VDT-PACE, VD-
PACE plus thalidomide; DCEP, dexamethasone, cyclophosphamide, etopo-
side, cisplatin; D-BEAM, dexamethasone, carmustine, cytarabine, etoposide,
melphalan.
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chain relapse, 23% had radiographic and/or clinical relapse.
In this series, only 21% of patients had received maintenance
therapy post-transplant.
The results of the 3 randomized trials investigating lena-
lidomide maintenance (CALGB 100104 [4], IFM 2005-02 [5],
and the Italian tandemASCT versusmelphalan, lenalidomide,
and prednisone [6]) and a fourth study (the HOVON-65/
GMMG-HD4 trial [7]) that incorporated bortezomib mainte-
nance have led to an increase in the number of patients
routinely receivingmaintenance therapyafter ASCT.Whether
relapse patterns are changing in the era of lenalidomide or
bortezomibmaintenance has yet to be established.Moreover,
when patients have asymptomatic relapse/progression on
maintenance therapy, it is unclearwhether the patient should
be continued on their currentmaintenance regimen,whether
the dose should be escalated, whether a different regimen
should be used, or evenwhether the patient should be taken
offmaintenance and simply observeduntil the time of clinical
progression. Our understanding of clonal heterogeneity and
the impact of clonal tiding would argue against the latter
option [8,9]. Trials exploring the addition of either dexa-
methasone or thalidomide to patients experiencing asymp-
tomatic relapse/progression on lenalidomide maintenance
are underway (NCT01463670, NCT01927718). This is based on
prior clinical studies showing the feasibility of combining the
2 immunomodulatory drugs together, along with dexa-
methasone, in the relapsed/refractory setting [10,11],
although this concept is tempered by the stronger rationale
for combining nonecross-resistant treatment strategies in
this setting, such as the use of proteasome inhibitors in
combination with other agents.Management of Relapse/Progressive Disease after First
ASCT
The 3 general approaches tomanagement of symptomatic
relapse after initial ASCT are reinduction followed by salvage
ASCT, reinduction followed by allogeneic SCT (AlloSCT), or,
most commonly, reinduction with continuation of conven-
tional dose chemotherapy using rational combinations of
novel therapies for relapsed/refractory disease. Currently,
only limited comparative data deﬁnitively support 1
approach over another, and prospective randomized studies
comparing novel agents to salvage transplant are needed.Reinduction Therapy before Salvage Transplant
As shown in Table 1, a multitude of salvage regimens are
available, ranging from single-agent therapies to doublets,
triplets, and multidrug chemotherapy regimens [12]. No
guidelines exist that dictate the choice of regimen, and, in
practice, the choice of the reinduction regimen generally
depends on patients’ responses to prior therapies, comor-
bidities, and burden of disease. In some settings, it is
reasonable to consider using the regimens that are similar to
ones used at an earlier point in disease management. There
are other scenarios where a different regimen might be
chosen. For example, persistent peripheral neuropathy from
prior bortezomib or relapse on maintenance lenalidomide
and/or bortezomib might merit the choice of regimens
containing alternative drugs, such as carﬁlzomib-based
therapy and/or a pomalidomide-containing regimen. In the
case described above, reinduction with a regimen such as
bortezomib, cyclophosphamide, and dexamethasone could
be considered.For patients with aggressive disease who relapse with a
high burden of systemic disease, we favor more intensive
salvage regimens that include 3 or 4 drug combinations
(Table 1). In this setting the use of chemotherapy with
selected novel agents serves as a means by which to more
rapidly debulk the disease and bridge the patient to a po-
tential salvage transplant. If reinduction therapy does not
provide a sufﬁcient response, an alternative regimen could
be chosen. However, retrospective studies have demon-
strated that a higher number of salvage regimens correlates
with inferior outcomes to salvage transplant in particular
[13,14]. In addition, proceeding with salvage ASCT or AlloSCT
for progressive disease is also associated with inferior out-
comes [13,15]. Thus, the decision to proceed with salvage
transplant should be readdressed if disease control cannot be
achieved after 1 to 3 reinduction regimens.Salvage ASCT
A number of reports have documented the feasibility of
performing salvage ASCTs [13,14,16e24]. As shown in Table 2,
overall response rates are generally high and transplant-
related mortality rates low. On average, the progression-
free survival (PFS) beneﬁt from a salvage transplant is
approximately half that of the PFS from the ﬁrst transplant.
There does not appear to be a clear signal that the type of
high-dose therapy given with the salvage ASCT has a signif-
icant impact on outcome (Table 1), and in the absence of
prospective trial data, many centers continue to use single-
agent high-dose melphalan, although other strategies such
as the integration of bortezomib administered with
melphalan in this setting has been evaluated [25,26].
Multiple studies have demonstrated that those patients
who relapse early after the ﬁrst ASCT derive less beneﬁt from
salvage ASCT and have worse outcomes. A cut-off time after
relapse from ﬁrst ASCT for considering patients for salvage
ASCT is a matter of debate. Jimenez-Zepeda et al. [21]
differentiated between patients that relapsed before or af-
ter 24 months from their ﬁrst ASCT. In that setting the me-
dian PFS was 9.83 versus 17.3 months and themedian overall
survival (OS) 28.5 versus 71.3 months, respectively. Fenk
Table 2
Summary of Retrospective Salvage ASCT Studies
Study n Maintenance
after First
ASCT
Median Time
Between
Transplants
(mo)
Reinduction
Therapy
Transplant
Regimen
Maintenance TRM (%) ORR
(%)
EFS or
PFS
(mo)
Elice
et al. [17]
26 None 20.4 “Polychemotherapy”
or Thal
MEL120 þ Bu None 1.9 88
Alvares
et al. [18]
83 CVAMP or other 15.6
Burzynski
et al. [19]
25 39 Thal (40%), Bor (36%),
Len (4%)
MEL200 or
MEL140
8 64 12
Olin
et al. [14]
41 Thal or
IFN (44%)
37 Thal (46%), Len (22%),
Bor (59%), all 3 (12%)
MEL200 (29%),
MEL80-180 (22%),
TBI-based (37%),
Bu/Cy (7%)
12% (IFN,
Thal, or Len)
7 55 8.5
Fenk
et al. [20]
55 IFN-a Thal,
or none
NR Thal or Len (76%),
Bor (47%)
MEL200,
Bu-MEL140,
MEL200 þ Bor
IFN-a Thal,
or none
5 (day 100) 85 14
Jimenez-
Zepeda
et al. [21]
81 None (67%),
Pred (22%),
Thal/Pred,
IFN
NR Multiple regimens Primarily MEL200 Pred, Thal,
IFN, or none
2.6 (day 100) 97 16.4
Shah
et al. [22]
44 30 Multiple regimens MEL200 or MEL
with Bu, topotecan,
Cy, arsenic trioxide,
arsenic trioxide þ
Bor, TBI, or
busulfan þ
gemcitabine
Thal, Len,
Bor, or none
2 (day 100) 90 12.3
Chow
et al. [23]
30 Median time
to relapse
after ﬁrst
auto of 30.2 mo
VAD (30%), Thal-based
(47%), Len-based (3%),
Bor-based (3%),
Mel-based (10%),
other (6.7%)
MEL200 (63%),
MEL200þBor (3%),
BuMel (10%),
MEL100-140 (23%)
67% 3 (at 100 days)
7 (at 2 yr)
88 22
Michaelis
et al. [24]
187 32 (median
time from
AHCT1 to
relapse/prg
18 mo)
MEL (84%), MEL þ
TBI (2%), MEL þ
others (9%),
BuCy (3%),
None (71%), Thal
or Len (11%),
IFN/IL-2 (7%),
steroid (5%),
Bor (5%),
other (2%)
2 (at 1 yr)
4 (at 3 yr)
68 11.2
Gonsalves
et al. [13]
98 46 Bor (50%), Len (40%),
Thal (32%)
MEL200 or
MEL140 (91%)
20% (not speciﬁed) 4 86 10.3
TRM indicates treatment-related mortality; ORR, overall response rate; EFS, event-free survival; Bu, busulfan; VAD, vincristine, doxorubicin, dexamethasone;
CED, cyclophosphamide, etoposide, dexamethasone; C-VAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; NR, not reported; CVAMP, vincris-
tine, doxorubicin, methylprednisolone, cyclophosphamide; TBI, total body irradiation.
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those patients with an initial remission time between 25 and
36 months. Chow et al. [23] reported that with using cut-offs
of under 18 months, 18 to 36 months, and more than 36
months, the median PFS after salvage ASCT was 4.2, 13.8, and
49.1 months (P< .0001) respectively, with median OS of 10.7,
30.9, and 86.1 months (P < .0001), respectively. A report
analyzing 187 patients who underwent salvage ASCT in a
Center for International Blood and Marrow Transplant
Research trial demonstrated that those patients who
relapsed 36 months or more after the ﬁrst transplant derived
greater beneﬁt from the second transplant (longer PFS and
OS) than those who relapsed early, which provides an
important benchmark [24].
Whether salvage ASCT yields better outcomes than
salvage chemotherapy is not completely understood. In a
retrospective comparison of patients undergoing second
ASCT versus no second ASCT, Elice et al. [17] reported no
difference in OS (P ¼ .21). Alvares et al. [18] reported no
difference in either EFS (1.3 versus 0.9 years, P ¼ .73) or OS
(2.9 versus 1.7 years, P ¼ .07) for patients who underwent
salvage ASCT versus other therapy at time of relapse from the
ﬁrst ASCT. A retrospective analysis by Gonsalves et al. [13]
revealed that for patients who received a salvage ASCT, the
median OS from time of diagnosis was 101.6 months versus92 months for those who did not receive a salvage ASCT (P ¼
.1). Interestingly, the median OS from time of relapse after
the ﬁrst transplant was 57 months for patients receiving
salvage ASCT versus 46months for those who did not receive
salvage ASCT (P ¼ .01). Thus, in general, retrospective data
have suggested a possible trend toward improved survival
with salvage transplant but not one that was signiﬁcantly
different and was in fact best seen in those patients with a
larger progression-free interval from ﬁrst transplant.
A recent multicenter, randomized, phase III study
compared salvage ASCT with cyclophosphamide (400 mg/
m2/wk for 12 weeks) [27]. In this study patients were
eligible if they had progressed or relapsed at least
18 months after the initial ASCT. All patients received
reinduction therapy with a bortezomib-doxorubicin-
dexamethasone regimen and were randomized to
either ASCT or cyclophosphamide. Although the median
time to progression was longer in the ASCT arm (19
versus 11 months, P < .0001), the OS did not differ.
Because salvage regimens are now available that are more
effective than single-agent cyclophosphamide, additional
prospective randomized trials comparing novel therapies
(eg, pomalidomide-bortezomib-dexamethasone, pomali-
domide-carﬁlzomib-dexamethasone, or other novel agent
combinations) with salvage ASCT are needed.
Table 3
Summary of Studies Evaluating Salvage ASCT vs. Salvage AlloSCT
Study n Nonrelapse Mortality
Rate (Auto vs. Allo) (%)
Response Rate
(Auto vs. Allo) (%)
Median PFS (Auto vs. Allo) Median OS
(Auto vs. Allo) (mo)
Wirk et al. [28] 27 (auto)
19 (allo)
3.7 vs. 5.3 (P ¼ .9) 81 vs. 58 19 vs. 6 mo (P ¼ .156) 23 vs. 19 (P ¼ .255)
Qazilbash et al. [29] 14 (auto)
26 (allo)
14 vs. 27 64 vs. 69 6.8 vs. 7.3 mo 29.5 vs. 13
Mehta et al. [30] 42 (auto)
42 (allo)
9.5 vs. 50 81 vs. 62 (P ¼ .054) 3-yr EFS: 25% vs. 20% 32 vs. 20 (P ¼ .013)
Freytes et al. [31] 137 (auto)
152 (allo)
2 vs. 13 (P < .001) at 1 yr NR 3-yr PFS: 12% vs. 6% (P ¼ .038) 3 yr: 46% vs. 20% (P < .001)
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Reduced-intensity conditioning AlloSCT in the salvage
setting is sometimes considered for younger patients with
good performance status and high-risk features, including
del 17p, t(4;14), t(14;16), or high-risk gene expression proﬁle,
high lactate dehydrogenase, or plasma cell leukemia. Pro-
spective randomized studies comparing salvage AlloSCTwith
salvage ASCT have not been performed. Table 3 summarizes
the retrospective analyses published comparing these 2 ap-
proaches. In aggregate, these studies demonstrate a higher
nonrelapse mortality rate with AlloSCT, and PFS/OS rates
favor salvage ASCT. These studies are limited by their retro-
spective nature and lack of information regarding risk status
based on cytogenetic data. Also, only a limited number of
studies have evaluated salvage AlloSCT versus no AlloSCT. As
summarized in Table 4, these retrospective analyses have
demonstrated improved PFS for patients undergoing salvage
AlloSCT but have not shown an OS beneﬁt. As the number of
effective regimens for relapsed/refractory disease continues
to increase, the role of salvage AlloSCT continues to be
deﬁned and evolve, with participation in clinical trials a
priority.Table 5
Novel Agents under Investigation for Myeloma
Agents
Proteasome inhibitors Ixazomib, marizomib, oprozomib
Monoclonal antibodies Anti-CS1: elotuzumab
Anti-CD38: daratumumab, SAR650984
Anti-CD138: indatuximab ravtansine (BT062)
Anti-CD56: lorvotuzumab
Anti-CD40: dacetuzumab, lucatumumabSalvage Regimens
As noted above, numerous options exist for relapsed/re-
fractory disease, and the numbers of effective and available
agents are increasing rapidly (Table 1). When the goal of
therapy is not subsequent transplant, the choice of salvage
regimen becomes more dependent on long-term tolerability
and efﬁcacy [33,34]. A randomized trial by Garderet et al.
[35] demonstrated that triplet therapy (bortezomib/thalid-
omide/dexamethasone) was associated with a higher
response rate and longer time to progression but also higher
incidence of grades 3/4 toxicity as compared with thalido-
mide/dexamethasone in patients with progressive or
relapsed disease after ASCT. Substantial clinical data support
the practice of retreating patients with agents to which they
have previously been exposed, particularly in the context of
different combinations [36,37]. The response rate and PFSTable 4
Summary of Studies Evaluating Salvage AlloSCT vs. No AlloSCT (Donor vs. No
Donor)
Study n Median PFS
(Donor vs.
No Donor)
Median OS
(Donor vs.
No Donor)
Patriarca
et al. [15]
75 (donor)
94 (no donor)
2-yr PFS: 42%
vs. 18% (P < .001)
2-yr OS: 54%
vs. 53% (P ¼ .329)
de Lavallade
et al. [32]
19 (donor)
13 (no donor)
3-yr PFS: 46%
vs. 8% (P ¼ .01)
3-yr OS: 50%
vs. 49% (P ¼ NS)
NS indicates not signiﬁcant.generally diminish with each subsequent line of therapy
[38], and outcomes after prior immunomodulator and/or
proteasome inhibitor exposure and failure are especially
poor [39].
As noted in Table 5, over 30 novel agents are currently
under various stages of investigation [33,40]. Particular
attention should be paid to the histone deacetylase inhibitor
panobinostat, the anti-CS1 monoclonal antibody elotuzu-
mab, and the anti-CD38 antibodies daratumumab and
SAR650984. The addition of panobinostat to bortezomib/
dexamethasone signiﬁcantly improved PFS (11.99 versus
8.08 months, P < .0001) in patients with relapsed/refractory
myeloma [41]. Although single-agent elotuzumab lacks ac-
tivity in relapsed/refractory myeloma patients, an objective
response rate of 82% was reported when this agent was
combined with lenalidomide/dexamethasone [42,43]. The
anti-CD38 antibodies daratumumab and SAR650984 have
shown impressive single-agent activity in heavily pretreated
patients and are being explored in combination with other
agents [44,45]. Thus, clinical trials should always be strongly
considered for patients with relapsed/refractory disease.RECOMMENDATIONS
As shown in Figure 1, we propose that the duration of
disease control after the ﬁrst ASCT plays an important role in
determining the subsequent treatment approach. For pa-
tients who relapse less than 18 months after transplant,
particularly those with high-risk disease features and young
age, we would consider reinduction therapy followed byAnti-BAFF: tabalumumab
Anti-IL6: siltuximab
Histone deacetylase
inhibitors
Vorinostat, panobinostat, romidepsin,
ricolinostat
Cell cycle inhibitors Seleciclib, MLN8237, ARRY-520, dinaciclib
Kinase/growth factor
inhibitors
Masitinib, dasatinib, enzastaruin,
GSK2110183, selumetinib, ibrutinib, LGH447
Bromodomain inhibitor CPI-0610
HSP90 inhibitors Tanespimycin, ganetsepib, ricolinostat
mTORC inhibitors MLN0128, INK128, everolimus, temsirolimus
Nuclear export inhibitor KPT330
PARP1/2 inhibitor Veliparib
Bcl-2 inhibitor ABT199
Alkylating agents Melﬂufen, TH-302
Figure 1. Algorithm for management of relapsed myeloma after ﬁrst ASCT. Participation in clinical trials at any point is encouraged. R/R indicates relapsed/refractory.
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agents. For those patients for whom AlloSCT is not feasible or
appropriate, then additional lines of salvage chemotherapy
incorporating novel agents or participation in a clinical trial
is recommended. We strongly consider salvage ASCT for
patients who achieved signiﬁcant long-term disease control
with ﬁrst ASCT (>36months). If such patients are not eligible
for a second ASCT because of age or other comorbidities, then
salvage chemotherapy or clinical trial is recommended as
above. Finally, the available data are less clear for guiding the
management of patients who achieved between 18 and 36
months of disease control from their ﬁrst ASCT. In this
setting, outside of a clinical trial, either salvage ASCT or
sequential lines of salvage regimens is reasonable.
CONCLUSIONS
Although most myeloma patients achieve disease control
with ASCT, almost all will subsequently relapse or progress,
necessitating additional treatment. Although there are a
large number of relapsed/refractory regimens fromwhich to
choose, and even more options likely in the future based on
the many agents currently in clinical trials, salvage ASCT
remains an important therapeutic approach. Although there
are limited prospective data, substantive retrospective data
suggest that the most important predictor of beneﬁt from
salvage ASCT is the time to progression from the ﬁrst ASCT.
However, because those studies were performed in an era
predating the use of next-generation novel agents such as
pomalidomide, carﬁlzomib, ixazomib, and others, as well as
histone deacetylase inhibitors and monoclonal antibodies,
there continues to be a critical need for prospective studies to
be performed. Likewise, it will be important for prospective
trials to be performed to determine the role of salvage
AlloSCT in selected patients in addition to other immuno-
logical strategies, with the overall goal of further improving
patient outcome in this otherwise incurable disease.
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